Posted by Michael Wonder on 30 Sep 2023
FDA grants first marketing authorisation for a DNA test to assess predisposition for dozens of cancer types
29 September 2023 - Today, the US FDA granted de novo marketing authorisation for the Invitae Common Hereditary Cancers Panel, an in vitro diagnostic test that can help detect hundreds of genetic variants associated with an elevated risk of developing certain cancers.
The test can also help identify potentially cancer associated hereditary variants in individuals with already diagnosed cancer. The test, which is the first of its kind to be granted FDA marketing authorisation, evaluates DNA extracted from a blood sample to identify variants in 47 genes known to be associated with an elevated risk of developing certain types of cancer.
